Abbott: Upgrade to Buy Ahead of Q1 — A Clearer Path to Rebound
We upgrade Abbott Laboratories (ABT) to Buy ahead of Q1 results. At $103.52, the shares trade below near-term averages with a PE ~27.6, a healthy dividend yield (~2.3%), and strong free cash flow ($7.4B). Recent weakness centers on diagnostics and nutrition, but medical devices growth, a manageable balance sheet (debt/equity 0.25), and the $21B Exa…